Novo Nordisk has announced a DKK 5.4 billion ($742 million) expansion of clinical-scale active pharmaceutical ingredient (API) manufacturing capacity. The investment  includes expansion of the company’s existing facilities in Bagsværd, Denmark, and the construction of a new plant.  

These expansions will provide capacity for developing Novo Nordisk’s future oral and injectable product portfolio. The investment project is expected to be finalized in 2024 and create approximately 160 new jobs. 

Source: Novo Nordisk